Biocon Biologics launches Yesintek biosimilar to Stelara in US: Our Bureau, Bengaluru Tuesday, February 25, 2025, 15:40 Hrs [IST] Biocon Biologics has announced that Yesintek (ust ...

Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

Russia's second-largest lender VTB Bank made record profits of 551.4 billion roubles ($6.3 billion) in 2024, its chief ...

Fresenius Medical Care FMEG.DE, the world's largest dialysis specialist, reported fourth quarter results slightly above ...

Pyzchiva, a treatment for plaque psoriasis, Crohn's disease, active psoriatic arthritis and ulcerative colitis, is Samsung ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Biocon added 1.36% to Rs 325.25 after the company announced that its subsidiary, Biocon Biologics (BBL), has launched YESINTEK (ustekinumab-kfce) in the United States.

Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Shares of firms like Biocon, LIC, NTPC Green, IREDA, Texmaco Rail, and others will be in focus on Tuesday's trade ...